Clinical Trials Logo

Clinical Trial Summary

To evaluate the usability and utility of the device, % agreement between the PID-RDT and the referent assay (serum/plasma), and % agreement between capillary blood and venous blood samples using the PID-RDT within confirmed PID patients prior to receipt of their monthly IV-Ig treatment.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05621876
Study type Observational
Source PATH
Contact Megan Parker
Phone 202.460.6239
Email mparker@path.org
Status Not yet recruiting
Phase
Start date May 15, 2024
Completion date September 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT01012323 - Clinical Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Patients With Primary Immunodeficiency Diseases Phase 3
Recruiting NCT05236764 - Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion N/A
Recruiting NCT05999422 - Exercise Capacity, Physical Activity Level and Quality of Life in Children With Primary Immunodeficiency
Not yet recruiting NCT05758506 - Developing a Screening Tool for Primary Immunodeficiency Disease (PID) in Pakistan